Dr. Howard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2200 Houpt Bldg, CB #7025
Chapel Hill, NC 27599Phone+1 919-962-6680Fax+1 919-966-2622
Summary
- Dr. James Howard is a neurologist in Chapel Hill, NC and is affiliated with University of North Carolina Hospitals. He received his medical degree from The Robert Larner, M.D. College of Medicine at The University of Vermont and has been in practice 43 years. He specializes in neuromuscular medicine and neurophysiology and is experienced in general neurology, electromyography, clinical research, neuromuscular medicine, and clinical neurophysiology.
Education & Training
- University of Virginia Medical CenterFellowship, Neuromuscular Medicine (Neurology), 1978 - 1979
- University of Virginia Medical CenterResidency, Neurology, 1975 - 1979
- Albany Medical CenterInternship, Internal Medicine, 1974 - 1975
- University of Vermont College of MedicineClass of 1974
Certifications & Licensure
- NC State Medical License 1979 - 2025
- VA State Medical License 1978 - 2020
- American Board of Psychiatry and Neurology Neurology
- American Board of Electrodiagnostic MedicineEMG
Awards, Honors, & Recognition
- Lifetime Achievement Award American Association of Neuromuscular and Electrodiagnostic and Medicine, 2024
- Distinguished Academic Achievement Award University of Vermont Larner College of Medicine, 2024
Clinical Trials
- Mycophenolate Mofetil in Myasthenia Gravis Start of enrollment: 2002 Sep 01
- Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Start of enrollment: 2008 Oct 01
- Efficacy of Methotrexate in Myasthenia Gravis Start of enrollment: 2009 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsUnited States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.Ali A Habib, Andrew J Klink, Srikanth Muppidi, Anju Parthan, S Chloe Sader
Journal of Neurology. 2024-09-01 - 2 citationsEculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.John F Brandsema, Matthew Ginsberg, Hideki Hoshino, Masakazu Mimaki, Satoru Nagata
Pediatric Neurology. 2024-07-01 - 1 citationsEvaluating algorithms for identifying incident Guillain-Barré Syndrome in Medicare fee-for-service claims.Samantha R Eiffert, Brad Wright, Joshua Nardin, James F Howard, Rebecca Traub
Global Epidemiology. 2024-06-01
Press Mentions
- Newsworthy from the School of Medicine, Week of December 27 – December 30December 30th, 2021
- Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMGOctober 2nd, 2019
- Ra Pharmaceuticals Announces Positive Top-Line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia GravisDecember 10th, 2018
- Join now to see all
Professional Memberships
- Fellow
- American Neurological AssociationMember
- Member
External Links
- Web pagehttps://www.med.unc.edu/neurology/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: